Universal flu vaccine developer BiondVax mulling IPO: Globes

Israel's BiondVax Pharmaceuticals, whose universal flu vaccine candidate has so far undergone a successful Phase II trial and is set for another next year, is thinking about a Wall Street IPO, according to Israeli newspaper Globes. Sources tell the paper the company, which has no revenue and cash reserves of 14.1 million shekels ($3.5 million), is exploring a conventional offering or listing American Depository Receipts for trading. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.